Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
YC-1
30
CHF
CHF 30.00
In stock
AG-CR1-0120-M0011 mgCHF 30.00
AG-CR1-0120-M0055 mgCHF 90.00
AG-CR1-0120-M02525 mgCHF 360.00
| Product Details | |
|---|---|
| Synonyms | 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole |
| Product Type | Chemical |
| Properties | |
| Formula | C19H16N2O2 |
| MW | 304.4 |
| CAS | 170632-47-0 |
| Purity Chemicals | ≥98% (NMR) |
| Appearance | White to pale yellow powder. |
| Solubility | Soluble in DMSO, methanol or dichloromethane. |
| Identity | Determined by 1H-NMR. |
| InChi Key | OQQVFCKUDYMWGV-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Nitric oxide (NO) independent, superoxide-sensitive soluble guanylyl cyclase (sGC) activator [1, 4].
- Induces concentration-dependent increase in cGMP levels [1, 4].
- Inhibits platelet adhesion to collagen [2, 8].
- Thombosis inhibitor [3].
- Non-specific phosphodiesterase inhibitor [5].
- Na+ channel blocker [6, 9].
- Anticancer compound [7, 8].
- HIF-α inhibitor [7, 10].
- Blocks angiogenesis. Tumor growth inhibitor [7, 10].
- Apoptosis inducer [11].
- NK cell differentiation enhancer [12].
- TRAIL sensitizer [13].
Product References
- YC-1, a novel activator of platelet guanylate cyclase: F.N. Ko, et al.; Blood 84, 4226 (1994)
- YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase: C.C. Wu, et al.; Br. J. Pharmacol. 116, 1973 (1995)
- YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice: C.M. Teng, et al.; Eur. J. Pharmacol. 320, 161 (1997)
- Mechanism of YC-1-induced activation of soluble guanylyl cyclase: A. Friebe & D. Koesling; Mol. Pharmacol. 53, 123 (1998)
- BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase: M. Koglin, et al.; BBRC 292, 1057 (2002)
- Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition: G. Garthwaite, et al.; Mol. Pharmacol. 61, 97 (2002)
- YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1: E.J. Yeo, et al.; J. Natl. Cancer Inst. 95, 516 (2003)
- Versatile pharmacological actions of YC-1: anti-platelet to anticancer: Y.S. Chun, et al.; Cancer Lett. 207, 1 (2004) (Review)
- A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain: D. R. Riddall, et al.; Mol. Pharmacol. 69, 278 (2006)
- Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading: D.H. Shin, et al.; Cancer Lett. 255, 107 (2007)
- YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway: S.Y. Wu, et al.; Br. J. Pharmacol. 155, 505 (2008)
- YC-1 enhances natural killer cell differentiation from hematopoietic stem cells: S. Yun, et al.; Int. Immunopharmacol. 10, 481 (2010)
- Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis: D. Finlay, et al.; PLoS One 5, e13375 (2010)
Related Products
